281 related articles for article (PubMed ID: 17310826)
41. Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53.
Reschner A; Bontems S; Le Gac S; Lambermont J; Marcélis L; Defrancq E; Hubert P; Moucheron C; Kirsch-De Mesmaeker A; Raes M; Piette J; Delvenne P
Gene Ther; 2013 Apr; 20(4):435-43. PubMed ID: 22809997
[TBL] [Abstract][Full Text] [Related]
42. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
[TBL] [Abstract][Full Text] [Related]
43. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
44. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways.
Kim HJ; Guo W; Park NH
Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530
[TBL] [Abstract][Full Text] [Related]
45. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
46. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
47. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
Stewart D; Ghosh A; Matlashewski G
J Virol; 2005 Jul; 79(14):8773-83. PubMed ID: 15994771
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.
Heideman DA; Steenbergen RD; van der Torre J; Scheffner M; Alemany R; Gerritsen WR; Meijer CJ; Snijders PJ; van Beusechem VW
Mol Ther; 2005 Dec; 12(6):1083-90. PubMed ID: 16085463
[TBL] [Abstract][Full Text] [Related]
49. Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis.
Seewaldt VL; Mrózek K; Dietze EC; Parker M; Caldwell LE
Cancer Res; 2001 Jan; 61(2):616-24. PubMed ID: 11212259
[TBL] [Abstract][Full Text] [Related]
50. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
51. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
52. Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.
Yi JW; Jang M; Kim SJ; Kim SS; Rhee JE
Oncol Rep; 2013 Apr; 29(4):1617-22. PubMed ID: 23404471
[TBL] [Abstract][Full Text] [Related]
53. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
54. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
Molinari M; Milner J
Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
[TBL] [Abstract][Full Text] [Related]
55. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells.
Huang H; Huang SY; Chen TT; Chen JC; Chiou CL; Huang TM
J Cell Biochem; 2004 Mar; 91(4):756-65. PubMed ID: 14991767
[TBL] [Abstract][Full Text] [Related]
56. Alteration of cell-cycle regulatory proteins in human oral epithelial cells immortalized by HPV16 E6 and E7.
Sdek P; Zhang ZY; Cao J; Pan HY; Chen WT; Zheng JW
Int J Oral Maxillofac Surg; 2006 Jul; 35(7):653-7. PubMed ID: 16513324
[TBL] [Abstract][Full Text] [Related]
57. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
58. Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids.
Isaacs JS; Chen P; Garza A; Hansen MF; Barrett JC; Weissman BE
Oncogene; 1997 Apr; 14(14):1669-78. PubMed ID: 9135068
[TBL] [Abstract][Full Text] [Related]
59. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.
Hamada K; Shirakawa T; Gotoh A; Roth JA; Follen M
Gynecol Oncol; 2006 Dec; 103(3):820-30. PubMed ID: 16908054
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation.
Sherman L; Jackman A; Itzhaki H; Stöppler MC; Koval D; Schlegel R
Virology; 1997 Oct; 237(2):296-306. PubMed ID: 9356341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
